The following represents disclosure information provided by authors of this abstract. The Gastrointestinal Cancers Symposium Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Positron emission tomography (PET) with 89Zr-labeled trastuzumab (89Zr-trastuzumab): Monitoring HER2 expression in HER2-positive gastric cancer in vivo.
Yelena Y. Janjigian
Disclosure not yet available
Nerissa T. Villegas
Disclosure not yet available
Jason P. Holland
Disclosure not yet available
Manish A. Shah
Disclosure not yet available
Vadim Divilov
Disclosure not yet available
David P. Kelsen
Disclosure not yet available
Jason S. Lewis
Disclosure not yet available